B7-H3/CD99 dual-target CAR-T cell therapy(University of Colorado)

N/A

Report date: 2026/04/23 20:00:25

Base Information

Drug NameB7-H3/CD99 dual-target CAR-T cell therapy(University of Colorado)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy > Dual-target CAR-T cell therapy

Mechanisms of ActionCD276 antigen modulatorsCD99 antigen modulators

TargetsCD276 antigenCD99 antigen

Therapy Area/IndicationsDiffuse Intrinsic Pontine Glioma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesUniversity Of Colorado

China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of Colorado

Inactive CompaniesN/A

Active IndicationsDiffuse Intrinsic Pontine Glioma

Inactive IndicationsN/A

Other Information

ATC CodeN/A